MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) Stock Competitors & Peer Comparison
See MIRA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for MIRA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MIRA | $0.63 | +1.78% | 26.9M | -0.44 | -$1.45 | N/A |
| LLY | $1,430.83 | +1.34% | 1.3T | 45.48 | $31.49 | +0.47% |
| JNJ | $280.20 | -0.68% | 675.9B | 26.17 | $10.73 | +1.88% |
| ABBV | $293.85 | +0.19% | 519.4B | 28.84 | $10.19 | +2.36% |
| MRK | $146.51 | -1.51% | 365B | 46.12 | $3.21 | +2.31% |
| NVS | $160.17 | -2.15% | 308.4B | 18.79 | $8.69 | +2.90% |
| AZN | $185.02 | -2.31% | 289.5B | 20.16 | $9.26 | +1.73% |
| AMGN | $466.45 | +1.31% | 251.4B | 20.79 | $22.37 | +2.14% |
| GILD | $169.98 | +0.39% | 211.9B | -438.13 | -$0.39 | +1.91% |
| NVO | $41.10 | -0.68% | 179.4B | 10.12 | $4.02 | +4.43% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
MIRA vs LLY Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, LLY has a market cap of 1.3T. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while LLY trades at $1,430.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas LLY's P/E ratio is 45.48. In terms of profitability, MIRA's ROE is -1.07%, compared to LLY's ROE of +0.84%. Regarding short-term risk, MIRA is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
MIRA vs JNJ Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, JNJ has a market cap of 675.9B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while JNJ trades at $280.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas JNJ's P/E ratio is 26.17. In terms of profitability, MIRA's ROE is -1.07%, compared to JNJ's ROE of +0.20%. Regarding short-term risk, MIRA is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
MIRA vs ABBV Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, ABBV has a market cap of 519.4B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while ABBV trades at $293.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas ABBV's P/E ratio is 28.84. In terms of profitability, MIRA's ROE is -1.07%, compared to ABBV's ROE of -2.03%. Regarding short-term risk, MIRA is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
MIRA vs MRK Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, MRK has a market cap of 365B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while MRK trades at $146.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas MRK's P/E ratio is 46.12. In terms of profitability, MIRA's ROE is -1.07%, compared to MRK's ROE of +0.05%. Regarding short-term risk, MIRA is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check MRK's competition here
Novartis AG (NYSE: NVS)
MIRA vs NVS Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, NVS has a market cap of 308.4B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while NVS trades at $160.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas NVS's P/E ratio is 18.79. In terms of profitability, MIRA's ROE is -1.07%, compared to NVS's ROE of +0.25%. Regarding short-term risk, MIRA is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
MIRA vs AZN Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, AZN has a market cap of 289.5B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while AZN trades at $185.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas AZN's P/E ratio is 20.16. In terms of profitability, MIRA's ROE is -1.07%, compared to AZN's ROE of +0.22%. Regarding short-term risk, MIRA is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
MIRA vs AMGN Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, AMGN has a market cap of 251.4B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while AMGN trades at $466.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas AMGN's P/E ratio is 20.79. In terms of profitability, MIRA's ROE is -1.07%, compared to AMGN's ROE of +0.86%. Regarding short-term risk, MIRA is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check AMGN's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
MIRA vs GILD Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, GILD has a market cap of 211.9B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while GILD trades at $169.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas GILD's P/E ratio is -438.13. In terms of profitability, MIRA's ROE is -1.07%, compared to GILD's ROE of -0.22%. Regarding short-term risk, MIRA is more volatile compared to GILD. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check GILD's competition here
Novo Nordisk A/S (NYSE: NVO)
MIRA vs NVO Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, NVO has a market cap of 179.4B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while NVO trades at $41.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas NVO's P/E ratio is 10.12. In terms of profitability, MIRA's ROE is -1.07%, compared to NVO's ROE of +0.54%. Regarding short-term risk, MIRA is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check NVO's competition here
Pfizer Inc. (NYSE: PFE)
MIRA vs PFE Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, PFE has a market cap of 167.3B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while PFE trades at $29.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas PFE's P/E ratio is 9.63. In terms of profitability, MIRA's ROE is -1.07%, compared to PFE's ROE of +0.05%. Regarding short-term risk, MIRA is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check PFE's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
MIRA vs CELG-RI Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, CELG-RI has a market cap of 157B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while CELG-RI trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, MIRA's ROE is -1.07%, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, MIRA is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for MIRA.Check CELG-RI's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
MIRA vs BMY Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, BMY has a market cap of 128.4B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while BMY trades at $62.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas BMY's P/E ratio is 10.59. In terms of profitability, MIRA's ROE is -1.07%, compared to BMY's ROE of +0.44%. Regarding short-term risk, MIRA is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check BMY's competition here
Sanofi (NASDAQ: SNY)
MIRA vs SNY Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, SNY has a market cap of 116.1B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while SNY trades at $48.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas SNY's P/E ratio is 10.51. In terms of profitability, MIRA's ROE is -1.07%, compared to SNY's ROE of +0.06%. Regarding short-term risk, MIRA is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check SNY's competition here
GSK plc (NYSE: GSK)
MIRA vs GSK Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, GSK has a market cap of 103.9B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while GSK trades at $50.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas GSK's P/E ratio is 11.07. In terms of profitability, MIRA's ROE is -1.07%, compared to GSK's ROE of +0.23%. Regarding short-term risk, MIRA is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check GSK's competition here
Biogen Inc. (NASDAQ: BIIB)
MIRA vs BIIB Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, BIIB has a market cap of 37.4B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while BIIB trades at $253.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas BIIB's P/E ratio is 15.99. In terms of profitability, MIRA's ROE is -1.07%, compared to BIIB's ROE of +0.02%. Regarding short-term risk, MIRA is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
MIRA vs HZNP Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas HZNP's P/E ratio is 61.86. In terms of profitability, MIRA's ROE is -1.07%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, MIRA is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
MIRA vs GRFS Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, GRFS has a market cap of 7.4B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while GRFS trades at $8.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas GRFS's P/E ratio is 10.06. In terms of profitability, MIRA's ROE is -1.07%, compared to GRFS's ROE of +0.09%. Regarding short-term risk, MIRA is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
MIRA vs OGN Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while OGN trades at $13.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas OGN's P/E ratio is 4.15. In terms of profitability, MIRA's ROE is -1.07%, compared to OGN's ROE of +0.22%. Regarding short-term risk, MIRA is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
MIRA vs AMRN Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, AMRN has a market cap of 242M. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while AMRN trades at $11.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas AMRN's P/E ratio is -117.00. In terms of profitability, MIRA's ROE is -1.07%, compared to AMRN's ROE of -0.04%. Regarding short-term risk, MIRA is more volatile compared to AMRN. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check AMRN's competition here
Scilex Holding Company (NASDAQ: SCLX)
MIRA vs SCLX Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, SCLX has a market cap of 11.3M. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while SCLX trades at $1.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas SCLX's P/E ratio is -0.04. In terms of profitability, MIRA's ROE is -1.07%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, MIRA is more volatile compared to SCLX. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
MIRA vs SCLXW Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, SCLXW has a market cap of 7.6M. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while SCLXW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas SCLXW's P/E ratio is N/A. In terms of profitability, MIRA's ROE is -1.07%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, MIRA is more volatile compared to SCLXW. This indicates higher risk in terms of short-term price fluctuations for MIRA.Check SCLXW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
MIRA vs CRXT Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, CRXT has a market cap of 0. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas CRXT's P/E ratio is -0.02. In terms of profitability, MIRA's ROE is -1.07%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, MIRA is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for MIRA.Check CRXT's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
MIRA vs BDSIW Comparison November 2026
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MIRA stands at 26.9M. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, MIRA is priced at $0.63 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MIRA currently has a P/E ratio of -0.44, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, MIRA's ROE is -1.07%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, MIRA is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for MIRA.Check BDSIW's competition here